General MedicationsINTRAVENOUSStandard
KYXATA
CARBOPLATIN
Standard Dose
80MG/8ML (10MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview KYXATA is listed in Drugs@FDA under application 219921 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient CARBOPLATIN Form and strength SOLUTION;INTRAVENOUS - 80MG/8ML (10MG/ML) Sponsor AVYXA HOLDINGS Submission history Latest submission status date: 2025-08-08 00:00:00.
Structured Monograph
Clinical summary
Approval overview KYXATA is listed in Drugs@FDA under application 219921 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient CARBOPLATIN Form and strength SOLUTION;INTRAVENOUS - 80MG/8ML (10MG/ML) Sponsor AVYXA HOLDINGS Submission history Latest submission status date: 2025-08-08 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.